Table 2:
Characteristics of Control subjects used to investigate endo-MT activation in vitro
| Control (N=12) | Values |
|---|---|
| Age (years) | 57 ± 14 |
| Sex: Male/Female (%) | 5/7 (42/58) |
| Race: White/Black/Other (%) | 9/1/2 (75/8/17) |
| BMI kg/m2 | 26.9 ± 1.5 |
| Comorbidities (0%) | |
| Hypertension | 3 (25%) |
| Obesity: BMI>30 kg/m2 | 0 |
| Type 2 diabetes | 0 |
| Atrial fibrillation/Atrial flutter | 0 |
| Medications (%) | |
| Diuretic | 2 (17) |
| ACE-I/ARB | 2 (17) |
| Beta-blocker | 0 |
| Calcium channel blocker | 0 |
| Aspirin | 2 (17) |
| Statin | 5 (42) |
Data are expressed as mean ± SD for continuous variables or numbers or percent (%) for categorical variables. BMI: body mass index; ACE-I: angiotensin-converting enzyme-inhibitor; ARB: angiotensin receptor blocker.